Catalogo dei prodotti della ricerca

GIUSTI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 883
EU - Europa 444
AS - Asia 136
AF - Africa 23
SA - Sud America 6
OC - Oceania 1
Totale 1.493
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 870
IT - Italia 184
SE - Svezia 120
IN - India 59
FI - Finlandia 32
SG - Singapore 31
BG - Bulgaria 26
CN - Cina 26
DE - Germania 24
TG - Togo 22
CA - Canada 11
IE - Irlanda 11
NL - Olanda 9
RO - Romania 8
ES - Italia 7
FR - Francia 7
GB - Regno Unito 7
AR - Argentina 6
HK - Hong Kong 6
TR - Turchia 5
BE - Belgio 3
IR - Iran 3
JP - Giappone 3
UA - Ucraina 3
MX - Messico 2
AU - Australia 1
CH - Svizzera 1
IL - Israele 1
KR - Corea 1
MK - Macedonia 1
NO - Norvegia 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 1.493
Salva come PNG Salva come JPEG
Città #
Fairfield 132
Ashburn 82
Chandler 60
Cambridge 56
Rome 55
Houston 52
Woodbridge 49
Wilmington 48
Seattle 39
Princeton 33
San Paolo di Civitate 31
Ann Arbor 28
Helsinki 27
Sofia 26
Lomé 22
Lawrence 21
New York 20
Millbury 17
San Diego 17
Boston 16
Beijing 15
Milan 13
Andover 12
Dearborn 10
Bremen 9
Dublin 9
Singapore 9
Norwalk 8
Federal 6
Padova 6
Plano 6
Toronto 6
Washington 6
Fremont 5
Istanbul 5
Bloomfield Hills 4
Hong Kong 4
Madrid 4
Sacramento 4
Barcelona 3
Boardman 3
Brussels 3
Catania 3
Groningen 3
Leawood 3
Ottawa 3
Breda 2
Bühl 2
Central 2
Durham 2
Ercolano 2
Imola 2
Kalāheo 2
Latina 2
Livorno 2
Mexico City 2
Morlupo 2
Naples 2
Pomezia 2
Pune 2
Raleigh 2
Rizziconi 2
Shanghai 2
Takamatsu 2
Thiene 2
Wuhan 2
Arnsberg 1
Balasore 1
Bari 1
Beauharnois 1
Brindisi 1
Buffalo 1
Chengdu 1
Drancy 1
Faenza 1
Fuzhou 1
Gavirate 1
Guidonia 1
Hanoi 1
Hounslow 1
Indore 1
Islington 1
Kashan 1
Levallois-perret 1
London 1
Menlo Park 1
Montreal 1
Muizenberg 1
Nürnberg 1
Olinda 1
Osaka 1
Paris 1
Prescot 1
Ramat Gan 1
Redwood City 1
Rieti 1
Rockville 1
San Francisco 1
Sandefjord 1
Scuola 1
Totale 1.067
Salva come PNG Salva come JPEG
Nome #
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab 99
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes 96
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 94
Pharmacogenetic assessment of toxicity in patients treated with taxane-based chemotherapy for solid tumors 70
Unexpected serious aplastic anemia from PD-1 inhibitors. beyond what we know 69
Genetic polymorphism can help physician choosing the best lung cancer chemotherapy 67
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 67
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment 67
Multidisciplinary approach to fetal adenocarcinoma of the lung: A case report 58
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification 57
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1 56
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy 55
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 54
New driver alterations in non-small cell lung cancer. A narrative review 52
null 50
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 46
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives 45
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%. A multicenter study with external validation 44
Next-Generation Sequencing in Clinical Practice. Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? 42
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 40
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational trial by FICOG 36
Statins and immunotherapy. Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC 34
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 33
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients. a multicenter study of clinicians’ attitudes 31
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care. a national survey 26
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 25
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer 24
Health as a human right, the right to life and the freedom to choose 23
CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach 21
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 20
null 17
null 17
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials 16
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO) 13
10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status 13
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 13
Efficacy and safety of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis 12
Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report 11
[Immunotherapy in non-small cell lung cancer patients: back to the future.] 11
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 11
null 10
null 10
ACCESS TO EARLY PHASE CLINICAL TRIALS AT THE TIME OF THE COVID-19 PANDEMIC: AN ITALIAN SURVEY 9
1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis 8
Training and telemedicine: the key to the palliative medicine specialist shortage? 2
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 2
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 1
Totale 1.677
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.702
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.702
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201942 0 0 0 0 0 0 0 0 0 10 17 15
2019/2020240 15 15 26 6 20 26 27 19 29 29 16 12
2020/2021217 12 8 13 15 2 6 16 29 22 34 24 36
2021/2022380 8 6 13 13 56 16 23 24 40 31 100 50
2022/2023443 81 108 41 27 40 30 5 63 31 4 9 4
2023/2024274 17 36 14 25 41 68 6 42 1 24 0 0
Totale 1.677